With pressure mounting on drugmakers to make clinical trial data more transparent, Pfizer has started to take steps to open up its results, unveiling more concrete details and a timeline for adoption this week.
Since 1888, the U.S. has published weekly reports on cases of notifiable diseases, building a huge trove of data in the process. The usefulness of this data was limited by its format, which stopped researchers from effectively mining it for insights, but a massive digitization project has now opened up the information.
The rise of cybersecurity threats gives biopharma and other industries a new and unfamiliar problem that they are ill-equipped to handle alone. In response, an increasing number of biopharma companies are outsourcing cybersecurity activities, a strategy that has been vindicated by a new report.
Speaking at an investor day late last week, Novartis chief financial officer Harry Kirsch outlined how the company plans to generate "substantial savings" by working with external data management vendors.
Frost & Sullivan predicts the falling cost of next-generation sequencing will cause the informatics market to triple in value by 2018.
BlackBerry phones are a defining tech of the first decade of the 21st Century, a time when suited Big Pharma execs used the devices to facilitate multi-billion dollar takeovers. At Pfizer, the mega-merger era it helped create is over, and now its relationship with BlackBerry is coming to a close, too.
Rising use of Fitbit wristbands, Withings scales and other self-tracking devices mean individuals have access to a pool of personal health data that in some respects far exceeds what clinical trials gather. Now, Validic has secured funding from Dallas Mavericks-owner Mark Cuban to bring the devices into healthcare.
In the flurry of chatter about the implications of last month's government shutdown, cybersecurity experts tried to get one point across--the furloughing of staff makes us vulnerable. With fewer staff guarding the U.S., the fear was hackers would strike. Now, the experience of FDA shows fears were well founded.
Over the past few years Medidata has frequently spoken of its efforts to grow sales of its Rave electronic data capture (EDC) platform by pinching clients competitors, notably Oracle. Now, having expanded its relationship with Alcon, Medidata is looking to make inroads with Novartis.
The falling cost of sequencing has created a new problem for research institutions--where to put all the data. At the Wellcome Trust Sanger Institute, 30 DNA sequencers generate a terabyte a day, meaning its 22 petabytes of storage is filling up. The time for a rethink on how it stores data has arrived.